1183 related articles for article (PubMed ID: 16532500)
1. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
2. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
3. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
4. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
Rüter B; Wijermans PW; Lübbert M
Cancer; 2006 Apr; 106(8):1744-50. PubMed ID: 16532502
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
6. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
7. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
8. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
Pitako JA; Haas PS; Van den Bosch J; Müller-Berndorff H; Kündgen A; Germing U; Wijermans PW; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():25-31. PubMed ID: 16292666
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL
J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635
[TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH
Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692
[TBL] [Abstract][Full Text] [Related]
12. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
[TBL] [Abstract][Full Text] [Related]
13. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
[TBL] [Abstract][Full Text] [Related]
14. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
[TBL] [Abstract][Full Text] [Related]
15. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
Becker H; Suciu S; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Hagemeijer A; Schaefer HE; Fiaccadori V; Baron F; Ganser A; Aul C; de Witte T; Wijermans PW; Lübbert M
Ann Hematol; 2015 Dec; 94(12):2003-13. PubMed ID: 26400023
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
17. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
[TBL] [Abstract][Full Text] [Related]
19. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
